Prior to expanding into central lab services the contract research organisation (CRO) outsourced these activities to its partners. Max Neeman intends to continue these relationships and supplement them with its in-house capabilities.
Ajoy Kumar, CEO of Max Neeman, explained: "We believe in continually expanding our service list and will continue to work closely with existing central lab partners to provide accurate results in the shortest possible turn around time.”
Study requirements will be compared to in-house and outsourced capabilities to ensure that the central lab services Max Neeman offers clients are suitable for the trial, added Kumar.
The site
The central lab is housed in a Max Healthcare hospital and has achieved National Accreditation Board for Testing and Calibration Laboratories (NABL) 15189:2007 / National Accreditation Board for Hospital and Healthcare Providers (NABH) accreditation.
Max Neeman has equipped the lab to be fully automated and operate 24/7. Services include hematology, histopathology, cytopathology, biochemistry, immunology, serology and flow cytometry.
For the Phase II oncology trial Max Neeman will provide serum cytokine analysis, peripheral T cell assays, immunocytohistochemistry, human leukocyte antigen (HLA) typing and other services.
EDC offering
Earlier this year Max Neeman enhanced its electronic data capture (EDC) offering through an agreement with Germany-based Amedon. The deal added Amedon’s EDC tool to Max Neeman’s offering.
Amedon designed its system to ease data entry and capture at the site end, offer serious adverse event reporting alerts and allow for direct capture of laboratory inputs.
This agreement was followed earlier this month by a deal to provide EDC for Phase IV trials. Under the terms of the deal, Max Neeman is providing EDC for trials run by the International Collaborative Cancer Group and Institute of Cancer Research Clinical Trials and Statistics Unit.